It is commonly recognized that large tumor size, lymph node involvement, high serum level of carbohydrate antigen 19-9 (CA 19-9) as well as main driver gene alterations (KRAS, TP53, CDKN2A, SMAD4) are associated with worse postoperative outcomes in PAAD patients2–4. The gene discussed is TP53; the disease is pancreatic adenocarcinoma.